Access the full text.
Sign up today, get DeepDyve free for 14 days.
References for this paper are not available at this time. We will be adding them shortly, thank you for your patience.
Haematologia , Vol. 32, No. 2, pp. 169– 173 (2002) Ó VSP 2002. Also available online - www.vsppub.com Case report Low dose melphalan is a treatment option in elderly patients with high risk myelodysplastic syndrome or secondary acute myeloblastic leukaemia KONSTANTINOS ANARGYROU, GEORGE VAIOPOULOS, EVANGELOS TERPOS, MARIA TSIRONI, KONSTANTINOS KONSTANTOPOULOS, MICHAEL SAMARKOS and JOHN MELETIS ¤ First Department of Internal Medicine, University of Athens School of Medicine, Laiko General Hospital, Athens, Greece Abstract —We present the case of a 71 year-old man with secondary acute myeloblastic leukemia, who was successfully treated with low dose melphalan plus Epo plus G-CSF. We treated the patient with 2 mg of melphalan once a day orally, G-CSF 5 mg/kg 3 times a week and Epo 10.000 ui subcutaneously 3 times a week until the maximum response was obtained. Complete remission was achieved after 16 weeks of continuous treatment. Treatment-related toxicity was not signi cant. We recommend the use of low dose melphalan in elderly patients with high risk MDS as a treatment option. Key words : Myelodysplastic syndrome; MDS; refractory anemia; blasts; RAEB; RAEB-t; secondary leukemia; AML-MDS; melphalan treatment. INTRODUCTION Myelodysplastic syndromes (MDSs) are a heterogeneous group of bone marrow clonal disorders
Haematologia – Brill
Published: Jan 1, 2002
Keywords: RAEB-T; BLASTS; REFRACTORY ANEMIA; SECONDARY LEUKEMIA; MELPHALAN TREATMENT; MYELODYSPLASTIC SYNDROME; RAEB; MDS; AML-MDS
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.